849472-99-7

Basic information

• Product Name: 1-N-BENZYL-1-N-METHYL-2-BOC-ETHANE-1,2-DIAMINE
• Synonyms: 1-N-BENZYL-1-N-METHYL-2-BOC-ETHANE-1,2-DIAMINE
• CAS NO: 849472-99-7
• Molecular Formula: C₁₅H₂₄N₂O₂
• Molecular Weight: 264.367
• Mol File: 849472-99-7.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-N-BENZYL-1-N-METHYL-2-BOC-ETHANE-1,2-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BENZYL-1-N-METHYL-2-BOC-ETHANE-1,2-DIAMINE(849472-99-7)
• EPA Substance Registry System: 1-N-BENZYL-1-N-METHYL-2-BOC-ETHANE-1,2-DIAMINE(849472-99-7)

Safety Data

• Hazardous Substances Data: 849472-99-7(Hazardous Substances Data)

Usage

Molecular structure

A derivative of ethane-1,2-diamine with a benzyl group attached to the nitrogen atom at the first position and a methyl group at the nitrogen atom in the second position. The BOC (tert-butyloxycarbonyl) group is attached to the amine functionality.

Usage

It is used as a precursor in organic synthesis, which means it can be used to create more complex organic compounds.

Chelating agent

The compound is based on ethane-1,2-diamine, which is a chelating agent. Chelating agents are used to bind and remove metal ions from a solution.

Manufacturing

The compound is commonly used in the manufacturing of pharmaceuticals and agrochemicals.

Chemical modifications

The presence of a benzyl and a methyl group in the molecule provides opportunities for further chemical modifications. This allows for the compound to be tailored for specific applications.

Protecting group

The BOC (tert-butyloxycarbonyl) group serves as a protecting group for the amine functionality. This allows for controlled reactions in the synthesis of more complex organic compounds.

Potential applications

The compound has potential applications in the pharmaceutical, agrochemical, and chemical industries.

Upstream product

• 96628-67-0 2-(tert-butoxycarbonylamino)ethyl methanesulfonate 
• 103-67-3 benzyl-methyl-amine 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 50-00-0 formaldehyd 
• 174799-52-1 tert-butyl {2-[benzylamino]ethyl}carbamate 
• 74-88-4 methyl iodide 
• 57260-73-8 N-BOC-1,2-diaminoethane 
• 100-52-7 benzaldehyde 
• 100-44-7 benzyl chloride 
• 101-98-4 2-(N-benzyl-N-methyl)amino-1-ethanol 
• 17542-47-1 benzyl-(2-chloro-ethyl)-methyl-amine 
• 14165-18-5 N-benzyl-N-methylethylenediamine 

Downstream Products

• 122734-32-1 tert-butyl 2-(methylamino)ethylcarbamate 
• 1018814-79-3 (6R,12aR)-6-(benzo[d][1,3]dioxol-5-yl)-2-(2-(benzyl(methyl)amino)ethyl)-2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido-[3,4-b]indole-1,4-dione 
• 14165-18-5 N-benzyl-N-methylethylenediamine 

Relevant articles and documents

CRYSTAL FORM OF MONOMETHANESULFONATE OF DEUTERATED 3-(4,5-SUBSTITUTED AMINOPYRIMIDINE)PHENYL COMPOUND AND PREPARATION METHOD THEREFOR

Disclosed in the present invention are a crystal form of monomethanesulfonate of a deuterated 3-(4,5-substituted aminopyrimidine)phenyl compound as represented by formula I, and a preparation method therefor. The crystal form is highly stable, can be used for treatment or prevention of diseases or conditions by means of epidermal growth factor receptors (EGFRs) in some mutation forms, can effectively inhibit the growth of a variety of tumor cells, and have an inhibiting effect on other proteases of EGFR and Her families, and thus can be used for preparing antitumor drugs.

An enzyme and its optional [...] modified ketone and inhibitor composition comprising (by machine translation)

PROBLEM TO BE SOLVED: ketone-containing acrylic misuse, abuse or overload is prevented for a new takable amt. provitamin drag pain. SOLUTION: a compound represented by the following formula is represented, in which the drag oxystyrene provitamin hydrocodone ketone-containing acrylic. Pre-selected drug profile is modified and the ketone and schisandrin [...] holding hung contg. compsn. method for administration to a patient. Selected drawing: no (by machine translation)

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF

The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.